Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 3 | ECTS2014 | Next issue

European Calcified Tissue Society Congress 2014

Prague, Czech Republic
17 May 2014 - 20 May 2014

Card image cap
European Calcified Tissue Society Annual Congress, 17 - 20 May 2014; Prague, Czech Republic

ba0003ht1 | (1) | ECTS2014

Atypical femoral fracture and bisphosphonate use: association with duration, cessation, gender, and type of bisphosphonate: a population-based study of 172 cases.

Schilcher Jorg , Koeppen Veronika , Michaelsson Karl , Aspenberg Per

Background: Bisphosphonate use is associated with an increased risk of atypical femoral fractures in women. The risk in men and the risk pattern dependent on treatment duration, recent use and type of bisphosphonate however remains unclear.Methods: All 5715 Swedish men and women, 55 years or older, with a fracture of the femoral shaft in the three-year period 2008–2010 were identified by the national patient registry. Radiographs were reviewed and w...

ba0003ht2 | (1) | ECTS2014

Osteoblast-specific ablation of p38α blunts the bone anabolic activity of parathyroid hormone

Thouverey Cyril , Caverzasio Joseph

Intermittent PTH administration (iPTH) increases bone mass in humans and animals. PTH exerts its effects by binding to PTH type 1 receptor (PTHR1) predominantly expressed in osteoblasts, resulting in activation of multiple downstream signaling pathways. In vitro investigations have suggested that p38 mitogen-activated protein kinase (MAPK) signaling is an important mediator of PTH-induced osteoblast functions.To evaluate the contribution of p38a...

ba0003ht3 | (1) | ECTS2014

Consistent, marked and rapid increases in hip and spine BMD with the PTHrP1-34 analog, abaloparatide (BA058), compared to placebo and teriparatide

Yates John , Alexandersen Peter , Krogsaa Annesofie , Nedergaard Bettina , Clarkin Marcie , Hattersley Gary , Karsdal Morten , Christiansen Claus

Background: Treatments that result in greater increases in bone mass of normal quality by increasing bone formation rather than decreasing resorption are needed. Abaloparatide is a synthetic analog of PTHrP1-34 that has shown strong efficacy to increase bone mass and bone strength in animals. We conducted two phase 2 placebo-controlled studies both of which included abaloparatide 80 μg sc daily (ABL) in postmenopausal women with osteoporosis. Study 1 also inclu...

ba0003ht4 | (1) | ECTS2014

Sclerostin prevents mice from osteoarthritis despite high subchondral bone accretion

Bouaziz Wafa , Funck-Brentano Thomas , Lin Hilene , Marty Caroline , Come Dominique , Hay Eric , Cohen-Solal Martine

Purpose: Sclerostin, a Wnt inhibitor produced by osteocytes that regulate bone remodelling, might be involved in cartilage metabolism. Therefore, we assessed the effect of sclerostin in osteoarthritis using SOST-deficient mice.Methods: SOST-KO and wild type (WT) mice underwent partial meniscectomie (Mnx). Mice were sacrificed at 4, 6 or 9 weeks after Mnx to analyze i) bone volume (BV/TV) at the femoral condyle, ii) osteophyte volume (microCT), iii) carti...

ba0003ht5 | (1) | ECTS2014

Skin inflammation causes bone loss with reduced bone formation through systemic IL-17A release

Uluckan Ozge , Keller Johannes , Karbach Susanne , Croxford Andrew , Finzel Stephanie , Koenders Marije , Berg Wim Van Den , Amling Michael , Waisman Ari , Schett Georg , Wagner Erwin

Patients with chronic inflammatory diseases such as psoriasis are at high risk for developing osteoporosis. Psoriatic arthritis patients exhibit bone loss caused by increased bone resorption through activation of osteoclasts. However, it is not clear whether psoriasis can lead to bone loss in the absence of arthritis. Using mouse models with skin inflammation as well as psoriasis patient samples, we show that increased circulating IL-17A from the inflamed skin triggers bone lo...